Court reverses Risperdal decision

Share this article:

The Arkansas Supreme Court has put $1.2 billion into Johnson & Johnson's accounts.

The court ruled last week that a previous ruling, which slapped the drugmaker for violating Medicaid fraud and deceptive marketing practices, was erroneous because the wrong standard was used.

As explained by Reuters, the court reversed the financial penalty because the court said plaintiffs invoked a law that applies to healthcare facilities, as opposed to a corporation.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.